Spondyloarthritis

Primary care providers reported a lack of familiarity with axial spondyloarthritis features, contributing to fewer rheumatology referrals and a delay in diagnosis, noted a presenter at the 2021 North American Young Rheumatology Investigator Forum.

Shared features and clinical presentations can make diagnosis and management of psoriatic arthritis, non-radiographic axial spondyloarthritis and reactive arthritis particularly challenging, according to a speaker at the 2021 Rheumatology Nurses Society annual conference.

Most patients with active, radiographic axial spondyloarthritis who receive ixekizumab for 2 years show no radiographic disease progression, with low mean progression overall, according to a poster presentation at the EULAR 2021 Congress.

Given the limited awareness of non-radiographic axial spondyloarthritis, differentiating this disease from radiographic disease and prescribing appropriate therapy remains a key challenge, according to a presentation at the Biologic Therapies Summit.

European patients with axial spondyloarthritis wait an average of more than 7 years between the first appearance of symptoms and receiving a diagnosis, according to data published in Rheumatology.

Findings from the Live Yes! INSIGHTS survey from the Arthritis Foundation showed that out of some 40,000 patient responses, 100% reported experiencing some kind of pain within the last 7 days.

Women demonstrate higher axial spondyloarthritis disease burden, and more peripheral symptoms, than men, according to data published in The Journal of Clinical Rheumatology.

Studies that feature work participation as an outcome in patients with inflammatory arthritis should identify key contextual factors — such as job type or social security system — upfront, according to new “points to consider” from EULAR.

High disease activity and widespread pain in patients with axial spondyloarthritis are associated with the development of fibromyalgia, according to data published in Rheumatology.

Although secukinumab performs similarly to adalimumab in patients with spondyloarthritis who failed their first biological treatment, adalimumab proved superior in those who failed multiple biologics, according to data.